🔍

Sanjivani Paranteral Ltd (531569)

📊 BSE: 531569 🏢 Pharmaceuticals 📢 Latest filing: 23 Sep 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Sanjivani Paranteral's revenue was ₹23.8 Cr (+33.3% year on year, +80.5% on the previous quarter), and net profit ₹2.5 Cr (+43.9% year on year); the operating margin was 17.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹23.8	+33.3%	+80.5%
Operating profit	₹4.2	+58.0%	+165.6%
Net profit	₹2.5	+43.9%	+352.7%
EPS (₹)	2.03	+42.0%	+351.1%
Operating margin	17.5%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Sanjivani Paranteral Clarifies ₹5.80 Cr Warrant Proceeds Use for Capex and Subsidiary

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 23 Sep 2026, 03:48 PM

Sanjivani Paranteral has provided detailed utilization plans for proceeds from its proposed issuance of up to 5,00,000 convertible warrants following a query from BSE. The company plans to deploy approximately ₹5.80 crore of warrant proceeds towards capex and subsidiary working capital needs. Specifically, ₹1.57 crore is earmarked for capex (new machinery, HVAC systems, and utilities), while ₹9.38 crore represents the company's share of its subsidiary's ₹15.64 crore working capital requirement. The remaining funding balance will be met through internal accruals.

Clarified use of proceeds for the proposed issuance of up to 5,00,000 convertible warrants
Allocated ₹1.57 crore towards machinery, HVAC systems, and plant utilities capex
Earmarked funding towards subsidiary working capital needs, where company share is ₹9.38 crore out of total ₹15.64 crore
Total warrant proceeds utilization specified at approximately ₹5.80 crore, with remainder funded via internal accruals

💡 Track the receipt of final in-principle approval from BSE and subsequent warrant allotment pricing and execution timelines.

Sanjivani Paranteral Sets Sept 9, 2026 Record Date for 32nd AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 10:24 PM

Sanjivani Paranteral Limited has scheduled its 32nd Annual General Meeting (AGM) for Wednesday, September 16, 2026, to be conducted via video conferencing. The company fixed September 9, 2026, as the record/cut-off date to determine member eligibility for remote e-voting. Remote e-voting is scheduled to run from September 13 to September 15, 2026. The ordinary business includes the adoption of FY2026 audited financial statements and the re-appointment of Director Ashwani Khemka.

AGM scheduled for September 16, 2026 at 11:00 AM IST via VC/OAVM
Record date / cut-off date for e-voting fixed as September 9, 2026
Book closure from September 10, 2026 to September 16, 2026 (both days inclusive)
Remote e-voting open from September 13, 2026 (9:00 AM) to September 15, 2026 (5:00 PM)
Director Ashwani Khemka proposed for re-appointment (remuneration of Rs. 12,50,000 per month)

💡 Shareholders holding equity shares as of the September 9, 2026 cut-off date can cast their votes electronically between September 13 and September 15, 2026.

Sanjivani Paranteral Sets Sept 9 Record Date; 32nd AGM Scheduled for Sept 16, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 10:22 PM

Sanjivani Paranteral Limited has announced that its 32nd Annual General Meeting (AGM) will be held via video conferencing on September 16, 2026. The company has fixed September 9, 2026, as the cut-off record date to determine eligibility for remote e-voting, which runs from September 13 to September 15, 2026. The register of members and share transfer books will remain closed from September 10 to September 16, 2026. Ordinary resolutions to be voted on include the adoption of FY26 financial statements and the re-appointment of Director Ashwani Khemka.

32nd AGM scheduled for September 16, 2026, at 11:00 AM IST via VC/OAVM.
Cut-off record date for e-voting eligibility fixed as September 9, 2026.
Book closure period scheduled from September 10, 2026, to September 16, 2026.
Remote e-voting window opens September 13, 2026 (9:00 AM) and closes September 15, 2026 (5:00 PM).
Agenda includes re-appointment of Ashwani Khemka (holding 36,32,102 shares, remuneration Rs 12,50,000/month).

💡 Shareholders holding shares on the September 9, 2026 cut-off date can cast their votes electronically between September 13 and September 15, 2026, or attend the virtual AGM on September 16, 2026.

Sanjivani Paranteral Convenes 32nd AGM on Sep 16, 2026; Re-Appointment of CMD on Agenda

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 10:18 PM

Sanjivani Paranteral Limited has scheduled its 32nd Annual General Meeting (AGM) for Wednesday, September 16, 2026, via video conferencing. Key agenda items include adopting the audited financial statements for FY 2025-26 and the re-appointment of Chairman & Managing Director Mr. Ashwani Khemka, who retires by rotation. The remote e-voting period runs from September 13 to September 15, 2026, with a cut-off date of September 9, 2026. Share transfer books will remain closed from September 10 to September 16, 2026.

32nd AGM scheduled for Wednesday, September 16, 2026, at 11:00 AM IST via VC/OAVM.
Cut-off date for e-voting entitlement set as Wednesday, September 9, 2026.
Remote e-voting window opens September 13, 2026 (9:00 AM) and closes September 15, 2026 (5:00 PM).
Register of Members and Share Transfer Books closed from September 10, 2026 to September 16, 2026.
Proposed re-appointment of CMD Ashwani Khemka, holding 36,32,102 shares, with monthly remuneration of Rs. 12,50,000.

💡 Eligible shareholders holding shares on September 9, 2026, may participate in e-voting from September 13 to September 15, 2026, and track AGM outcomes post-meeting.

Sanjivani Paranteral Files FY26 Annual Report; Exports Account for 78.5% of Revenue

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Aug 2026, 10:14 PM

Sanjivani Paranteral Limited has submitted its Annual Report and AGM notice for FY2025-26 pursuant to Regulation 34 of SEBI LODR Regulations. The filing highlights that exports contributed 78.5% to total revenue, with operations delivering an EBITDA margin of 16.4% and a PAT margin of 10.7%. The company expanded its presence into 4 new geographies with a 179-product portfolio and outlined FY27 growth drivers including contributions from SPL Infusion Pvt. Ltd. and Alevia Healthcare S.R.O.

Exports accounted for 78.50% of revenue in FY26, with domestic sales contributing 21.50%
Reported an EBITDA margin of 16.4% and a PAT margin of 10.7% for FY26
Portfolio spans 179 products across 25 export countries, adding 4 new geographies during the year
Manufacturing capacity includes 60 million IV fluid bottles and 720 million tablets annually

💡 Track shareholder voting outcomes at the upcoming AGM and monitor the commercial ramp-up of the SPL Infusion and Alevia Healthcare joint ventures in FY27.

44% PAT Growth in Q1 FY27; EBITDA Margins Expand to 18% on Export Recovery

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 14 Aug 2026, 04:20 PM

Sanjivani Paranteral reported a strong start to FY27 with total income rising 33.8% YoY to ₹23.99 Cr. Net profit grew 43.9% to ₹2.49 Cr, driven by a 61% surge in EBITDA as margins expanded by 305 bps to 18.01%. The performance was heavily anchored by exports, which contributed 90.5% of revenue (₹17.61 Cr), particularly from core markets in Latin America, CIS, and the Middle East. The company also noted a gradual scale-up of its Pune IV Fluid facility, which is expected to drive future volumes.

Total Income grew 33.81% YoY to ₹23.99 Cr for the quarter ended June 2026.
EBITDA margins improved significantly by 305 basis points to 18.01%.
Exports contributed 90.50% of total revenue, amounting to ₹17.61 Cr, showing 33.49% YoY growth.
Injectables segment remains the primary revenue driver, contributing 56.59% (₹11.01 Cr) of operations.
Net Profit (PAT) increased 43.94% YoY to ₹2.49 Cr compared to ₹1.73 Cr in the previous year.

💡 Monitor the utilization levels and commercialization progress of the Pune IV Fluid facility, as it is a key driver for future scale. Investors should also watch for any diversification in the domestic market to mitigate the 90%+ export concentration risk.

Sanjivani Paranteral Targets ₹145 Cr Revenue in FY27, Driven by New IV Fluid Plant Ramp-up

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 14 Aug 2026, 04:18 PM

Sanjivani Paranteral has transitioned to a multi-vertical platform with the commissioning of its Pune IV fluid facility, which has a 60 million bottle annual capacity. Management has issued an aggressive revenue guidance of ₹145 cr for FY27, a ~123% increase over FY26 revenue of ₹64.8 cr. The new IV fluid vertical alone is expected to contribute ₹60-65 cr in FY27, effectively doubling the company's historical revenue base. While the company maintains a low debt-to-equity ratio of 0.19x, the focus now shifts to executing the guided utilization ramp-up from 40% to 70% through the fiscal year.

FY27 revenue guidance set at ₹145 cr, compared to ₹64.8 cr achieved in FY26.
New Pune IV fluid plant adds 60 million bottles per year capacity, with utilization guided to reach 70% by Q4 FY27.
IV fluid segment generated ₹4.38 cr in Q1 FY27, with a full-year target of ₹60-65 cr.
Exports remain the core driver, accounting for 78.5% of FY26 revenue across 25 countries.
Promoter stake has increased from 28.87% in June 2025 to 31.26% as of March 2026.

💡 Investors should monitor the quarterly utilization levels of the Pune IV fluid plant and the progress of the Prague JV majority stake negotiations, which could provide further inorganic growth.

Sept 16 AGM Set as Sanjivani Paranteral Approves Q1 FY27 Results and FY26 Annual Report

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 14 Aug 2026, 02:15 PM

Sanjivani Paranteral's board approved the unaudited financial results for Q1 FY27 (ended June 30, 2026) on August 14, 2026. This follows a fiscal year (FY26) where revenue declined 7.6% to ₹64.76 Cr compared to ₹70.1 Cr in FY25. The company has scheduled its 32nd Annual General Meeting (AGM) for September 16, 2026, via video conferencing. A book closure period for share transfers is set from September 10 to September 16, 2026.

Approved unaudited financial results for the first quarter ended June 30, 2026
32nd Annual General Meeting scheduled for September 16, 2026
Book closure period for members set from September 10, 2026, to September 16, 2026
Board meeting conducted and concluded within 60 minutes (1:00 PM to 2:00 PM)
Appointment of HD & Associates as Scrutinizer for the upcoming AGM e-voting

💡 Investors should examine the full Q1 FY27 results to determine if the company has recovered from the sequential revenue drop seen in March 2026 (₹10.51 Cr vs ₹20.86 Cr in Dec 2025).

Sanjivani Paranteral Approves Q1 Results; 32nd AGM Scheduled for Sept 16, 2026

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 02:11 PM

Sanjivani Paranteral's board has approved the unaudited financial results for the quarter ended June 30, 2026. The company has scheduled its 32nd Annual General Meeting (AGM) for September 16, 2026, to be conducted via video conferencing. Additionally, the register of members and share transfer books will be closed from September 10 to September 16, 2026. The board also finalized the Annual Report and Director’s Report for the financial year 2025-26.

32nd Annual General Meeting (AGM) scheduled for September 16, 2026
Book closure period of 7 days from September 10 to September 16, 2026
Board meeting duration of 60 minutes (1:00 PM to 2:00 PM)
Approval of the Annual Report and Director’s Report for FY 2025-26

💡 Investors should review the detailed Q1 FY27 financial statements to check for revenue recovery following the sequential decline to Rs 10.51 Cr in the March 2026 quarter.

Aug 14 Board Meeting to Approve Q1 FY27 Results and FY26 Annual Report

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 10 Aug 2026, 04:49 PM

Sanjivani Paranteral has scheduled a board meeting for August 14, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The board will also consider the Annual Report for FY26 and finalize details for the 32nd Annual General Meeting (AGM). This meeting follows a fiscal year (FY26) where the company reported a revenue of Rs 64.76 Cr and a net profit of Rs 6.92 Cr. Investors will be watching for a recovery from the March 2026 quarter, which saw a sequential revenue decline to Rs 10.51 Cr from Rs 20.86 Cr in December 2025.

Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
Approval of the Annual Report and Director Report for the financial year ended March 31, 2026.
Fixing of date, venue, and time for the 32nd Annual General Meeting.
Appointment of M/s. HD & Associates as Scrutinizer for remote e-voting at the AGM.

💡 Monitor the financial results on August 14, 2026, to assess if the company can improve its operating profit margin, which stood at 14.5% for TTM FY26.

Rs 7.37 Cr Preferential Issue of Warrants to Promoter at Rs 147.39

🟢 POSITIVE ⭐ 6/10

FUNDRAISE 📅 23 Jul 2026, 08:15 PM

Sanjivani Paranteral's board has approved the issuance of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at a price of Rs 147.39 per warrant. The total fundraise aggregates to Rs 7.37 crore, which represents approximately 15.3% of the company's current net worth of Rs 48 crore. The warrants are convertible into equity shares within 18 months, and the issue price is slightly above the current market price of Rs 146.8. This infusion will increase the specific promoter's individual stake from 29.88% to 32.62% upon full conversion.

Issuance of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka
Total capital infusion of Rs 7,36,95,000 (Rs 7.37 Cr) at an issue price of Rs 147.39
Promoter's individual shareholding to increase from 29.88% to 32.62% post-conversion
Warrants are convertible into equity shares within a maximum period of 18 months
Board also approved material related party transactions with subsidiary SPL Infusion Private Limited

💡 Investors should monitor the upcoming postal ballot for shareholder approval and track the utilization of these funds, particularly regarding the material related party transactions with the subsidiary.

Rs 7.37 Cr Preferential Warrant Issue to Promoter at Rs 147.39

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 23 Jul 2026, 08:12 PM

Sanjivani Paranteral's board has approved a preferential issue of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka, aggregating to Rs 7.37 crore. The warrants are priced at Rs 147.39 each, which is a marginal premium to the current market price of Rs 146.8. This capital infusion represents approximately 15.4% of the company's current net worth (Rs 48 Cr) and will increase the individual promoter's stake from 29.88% to 32.62% upon conversion. The board also approved material related party transactions with its subsidiary, SPL Infusion Private Limited, pending shareholder approval.

Issue of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at Rs 147.39 per warrant.
Total fundraise amount of Rs 7,36,95,000 (Rs 7.37 Cr) to be received in cash.
Individual promoter shareholding to increase from 29.88% to 32.62% post-conversion.
Warrants are convertible into equity shares within a maximum period of 18 months from allotment.
Approval of material related party transactions with subsidiary SPL Infusion Private Limited.

💡 Investors should monitor the upcoming postal ballot for shareholder approval and watch for disclosures regarding the specific end-use of the Rs 7.37 crore proceeds.

Board meeting on July 23 to consider fundraise via warrants or convertible securities

🔵 WATCH ⭐ 7/10

FUNDRAISE 📅 20 Jul 2026, 06:56 PM

Sanjivani Paranteral has scheduled a board meeting for July 23, 2026, to evaluate raising capital through warrants, convertible securities, or a preferential/rights issue. The company currently has a market capitalization of Rs 178 Cr and a low debt-to-equity ratio of 0.19. This move follows a period of declining stock performance, with a 12-month return of -41.1%. Investors should monitor the board's decision for the specific quantum of funds and the potential impact on the current promoter holding of 31.26%.

Board meeting scheduled for July 23, 2026, to discuss multiple fundraising modes.
Proposed instruments include warrants, convertible securities, preferential issues, or rights issues.
Company market capitalization is Rs 178 Cr against a TTM revenue of Rs 65 Cr.
Promoter holding stands at 31.26% as of March 2026, which may be impacted by the fundraise.
Trading window remains closed until 48 hours after the June 2026 quarter results.

💡 Monitor the outcome of the July 23 board meeting for details on the fundraise size, pricing, and the identity of potential allottees if a preferential issue is chosen.

View All 531569 Announcements on Live Market Tracking →